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This paper studies global R&D investment as a novel variable to proxy for technological 
advances as a determinant of HCE growth with data from 1970 onwards of 35 OECD 
countries. The aggregate decade averages of OECD countries’ expenditure on R&D in 
sciences have a negative and significant relation with HCE growth. R&D investments may be 
contributing to the reduction of HCE growth. This challenges the view that innovation solely 
contributes to increasing growth of HCE and allows for the possibility of opposing effects. 
 








1. Introduction  
In the 1970s, health care expenditure (HCE) as share of GDP ranged between 2.2% and 7.8%. 
Today, the share of GDP apportioned to HCE lies at 9% on average in OECD countries and 
ranges from 4.3% to 17.2%, in Turkey and the USA respectively. In terms of HCE per capita, 
the increase is even higher as can be seen in Figure 1 panel A. The growth rate of HCE 
expenditure (dlnHCE), however, has been decreasing in recent decades (Figure 1 panel B). 
Despite better health outcomes, these large and growing costs are leading to funding problems 
for individuals as well as governments (Curristine et al., 2007). In order to better understand 
and predict the cost development of health care, it is crucial to determine the main drivers of 
HCE growth. This study examines the usefulness of a novel explanatory variable of HCE 
growth based on R&D investments. Since 1970, the effect of GDP growth is identified as a 
significant positive indicator of HCE growth rates (see e.g. Barros (1998) & OECD (2017)).  
Figure 1: Panel A depicts HCE and Panel B presents the growth of HCE (dlnHCE) by 
country over time in years based on OECD data. 
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Predicting HCE growth merely by GDP growth leaves a large fraction of its development 
unexplained. The debate about which other factors to consider is ongoing. Demographic and 
non-demographic aspects are important determinants to take into account. Demographic 
variables include variables such as infant mortality and life expectancy indicators (Marino et 
al., 2017). Previous studies find technology as an important non-demographic driver for HCE 
growth. Technological progress involves new medical and technical solutions to treat and 
prevent sicknesses. However, there are still methodological differences in how to quantify 
this effect (Sorenson et al., 2013). Technological progress has been mainly approximated by 
demographic variables (Marino et al., 2017). This approach runs risk of endogeneity issues.  
In order to avoid endogeneity issues, this paper employs an alternative strategy to include 
technological progress in the explanation HCE growth: It uses the ten-year average of the sum 
of international R&D investments in science as a novel indicator for technological progress. 
For this study, a new dataset has been created based on the OECD database. The application 
of the updated dataset on the existing model of Barros (1998) yields similar results as it did 20 
years ago. My results, using data of the last 4 decades, detailed below, show that GDP growth 
is a positive and significant indicator of HCE growth, while policy tools, ageing population, 
and type of financing are insignificant. Including the R&D variable shows that R&D 
expenditure has a small but significant negative effect on HCE growth. 
The paper is structured as follows. In Section 2, the literature review summarizes the current 
state of empirical findings. This section is split between demographic and non-demographic 
indicators, highlighting estimation methods of technological advances. In Section 3, the 
methodology of the new model including R&D expenditure in sciences and a description of 
the dataset are presented to the reader. In Section 4, the results of the study are presented. 
Section 5 summarizes the findings of the model including R&D expenditure in the description 
of HCE growth movements, discussing the limitations and possible future research ideas.  




2. Literature Review 
2.1. Level vs. growth studies 
Research focused on cross-country differences in HCE levels aims to understand the relative 
success of differing types of health care systems, the impact of ageing population, and other 
HCE-relevant factors. The reason to study level variations across countries is to find 
determinants that characterize more or less expensive health care systems or factors at 
specific points in time (Gerdtham et al., 1995). It is necessary to investigate the 
complementary side of the static analysis by means of understanding dynamic health care 
expenditure determinants, the growth determinants. Growth analysis serves to find possible 
convergences or trends in growth rates at differing expenditure levels. Previous growth 
studies have come to the interesting finding that variables such as population aging, type of 
health care system, and the existence of gatekeepers are not significant indicators of HCE 
growth (Newhouse, 1992; Barros, 1998; Ke et al., 2011). GDP growth however remains a 
significant indicator of HCE growth, still leaving more than 60% of HCE growth unexplained 
(see Table 2 column 5). The difference between HCE level and growth rate evolution over 
time can be seen clearly in Figure 1, panel A and B respectively. This paper focuses on the 
analysis of growth determinants. 
2.2. Demographic and non-demographic determinants1 
Despite differences in methodological approaches across studies examining HCE growth, 
generally the following main drivers are included: demographic factors, income changes, 
local health care systems, and technological advances (Marino et al., 2017). Furthermore, 
HCE per capita must be understood as the result of multiplying the amount of health care 
received per person by the cost of the average bundle of health services or products: 
 1  𝐻𝐶𝐸 𝑝𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎 = 𝑎𝑚𝑜𝑢𝑛𝑡 𝐻𝐶 𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑑  × 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐻𝐶. 
                                                
1 A more detailed literature overview can be found in Appendix A. 
2 Appendix B contains a detailed list of variables included in the data set with their 




HCE is noted in terms of purchasing power parity, financed by public and private funds 
(Huber, 2006). The amount of health care received is determined predominantly by 
demographic factors, such as age or indicators of proximity to death. The price of health care 
is determined mainly by non-demographic factors such as exogenous shocks induced by 
policy changes, higher living standards due to higher income of the population, and 
improvements in life sciences (Maisonneuve et al., 2016). In this paper, the explanatory 
variables are split in two categories: demographic and non-demographic indicators, as shown 
in Maisonneuve & Martins (2017). 
A demographic factor that appears to be a more significant determinant of HCE than age is 
the cost related to death (Aprile & Palombi, 2006). People in their last year of life incur costs 
that are up to 15 times higher than those that survive the year (Marino et al., 2017). In other 
words, it is not necessarily the ageing of the population that is leading to higher average HCE. 
Instead, the probability of dying increases with older age, shifting costs that used to be 
attributed to younger age groups to older age groups.  
The most relevant non-demographic factors include income levels, system types, and 
technological changes. Income changes are generally measured in terms of gross domestic 
product (GDP) per capita. Higher income is positively related with higher expectations of 
life-quality. Having good health is an important component of life-quality, as it allows for 
better access to education and the job market (Better Life Index, 2017). The causality can run 
in both directions. In this study the focus lies on higher income levels leading to higher HCE.  
In this context, it is also interesting to analyze the aspect of income elasticity toward health 
care expenditure. Income elasticity captures changes in the share of GDP allocated to health 
care when incomes rise. Most cross-country studies find that the income elasticity of HCE is 
positive (Marino et al., 2017). This means that health care can be considered a normal good. 
Furthermore, the average income elasticity of health care lies around 0.75 (Lago-Penas et al., 




2013). It has been found that there are differences between more and less developed countries, 
in short- and long-run analysis, and levels of income data aggregation (Okunade & 
Suraratdecha, 2000). Getzen (2000, p.259) claims that health care is an “individual necessity 
and a national luxury”.  
The relative income of other professions has also been assumed to have an effect on HCE. 
This effect is known as the Baumol effect. When productivity in a sector increases, the wages 
increase due to higher output capacity. If many sectors are increasing their productivity faster 
than the health care sector, wages in the health care sector will increase more than its actual 
productivity increase. This wage equalization is necessary to attract and maintain qualified 
talent in the labor-intensive health care industry. Especially labor-intensive industries, such as 
the health care industry, are known to have low productivity growth and are thus labeled as 
non-progressive (Baumol & Malach, 2009). The increasing productivity also leads to higher 
GDP, which is another channel through which GDP affects HCE. Due it its complex nature, 
difficulty to measure, and high dependency on the definition of what is a progressive and non-
progressive industry, the Baumol effect on HCE is debatable (Hartwig, 2008).  
System types are institutional characteristics, which differ between countries. These 
differences are known to have an effect on HCE levels. The health care systems aim to steer 
the demand and supply using different policy tools. For example, gatekeepers are proven to 
be relevant cost-containing factors within the in-patient sector (Joumard et al., 2010). 
Generally, countries have different sources of health care funding. The funding sources range 
from out-of-pocket payments, insurance companies, government budget, to non-profit 
organizations. The publicly funded part is the largest in most countries and is financed by 
means of general taxes, national insurances, or a combination of both. The most impactful of 
these with respect to HCE are payment reforms, gatekeeping implementations, and policies 
leading to an increased uptake of generics instead of pharmaceuticals. When analyzing the 




system effects, it is important to understand the different agents and their reactions to policy 
changes. The effects can be split in three broad perspectives: demand-agents, supply-agents 
and the financing body (Maisonneuve et al., 2016; Maisonneuve & Martins, 2017). In the 
case of private suppliers, the supply side is heavily driven by the degree of competition and 
market strength to set prices for health care products. In some cases, the providers are public, 
eliminating competition and increasing policy dependency. The demand side depends on the 
country-specific regulatory frameworks. There are differences between public- and private-
insurance-based funding schemes (Clements et al., 2012). 
2.3. Technological Innovation  
Technology is defined as “the application of scientific knowledge for practical purposes” 
(Oxford Dictionaries, 2017). Technological progress occurs in different developmental stages. 
First, the creation aspect: after a long period of research and development (R&D) a new 
innovative product or process is developed. This extends the global technological frontier. 
Second, the diffusion: a new technology can spread across industries and geographically. This 
research will focus on the first stage. Technological innovation in the health care sector can 
occur in the following four broad fields: Patient care and services, pharmaceuticals and 
biochemistry, machinery (medical devices and advanced equipment used in medicine), and 
data collection and analytics. Countries and companies invest in new technologies in health 
care with the goal to increase quality, reach, and effectiveness of health services, equipment, 
and medications. Attempts to measure the effects of technological change have led to varying 
results due to differing methodological approaches and spectra of inclusion of technological 
advances (Cutler & McCellan, 1996; Baker & Wheeler, 1998; Murthy & Okunade, 2002). 
The fact that technological change is a very broad term and affects different factors across 
medical areas makes its effect on HCE growth difficult to measure. Despite the ongoing 
debate on measurement tools, the common conclusion is that innovation in health care 




technology is a crucial determinant of health care expenditure growth (Maisonneuve & 
Martins, 2017). 
Technological innovation in health care leads to higher life quality and healing of a wider 
spectrum of diseases resulting in longer life expectancies. Many studies have used 
demographic indicators such as life expectancy and infant mortality rates to proxy for 
technological advances (Braendle & Colombier, 2015). These demographic indicators are 
however riddled with multicollinearity issues between other explanatory variables. For 
example, there exists correlation between the share of people above the age of 65 over time 
and life expectancy by year of birth. A new attempt by Maisonneuve and Oliveira Martins 
(2017) uses a self-created proxy indicator to estimate technological progress. It contains 
admitted patents and R&D statistics, which are able to explain around one-third of the HCE 
residual, but the construction of the proxy is open to debate. 
Beyond the discussion on measurement tools of technology, there are also arguments whether 
the effect of technological innovation on HCE growth is positive or negative. Looking back at 
equation (1), the reasoning for an increase in health costs is that technological progress has 
been extending lives of people with previously fatal diseases, adding higher “up keeping 
costs” per person to the existing financial burden of medical expenditure (Moise, 2003; 
Marino et al., 2017). The rationale for a negative relation between technological advances in 
health care and HCE growth is that more advanced technologies allow for more efficient and 
effective care of patients. An example of large gains in cost-saving opportunities in hospitals 
can be achieved by improved IT systems supporting patient data management, accelerating, 
and improving precision of disease diagnostics (Hillestand, et al., 2005). These gains have 
been measured by variables such as average length of hospital stay or number of complex 
surgeries (Cutler & McCellan, 1996). In the empirical application, it is important to be aware 
of these opposing effects. In the case in which their effects are perfectly balanced, the result 




of technological advances may be cancelled out. This leads to the research question of this 
study: How does R&D expenditure in sciences affect HCE growth?  
It is important to note that R&D expenditure in sciences may not explain all of the residual 
movements, as it is only one component of several making up the price of new technology. 
Another possible shortcoming is that medical technology improvements take a long time to be 
developed, tested, and finally implemented. The actual effect of R&D may occur only after 
many time lags. This will be explored in the empirical analysis below. 
2.3 Contribution to existing research  
This paper applies a novel approach by estimating improved technology in the health care 
sector by R&D investments in sciences. R&D expenditure in sciences includes technological 
improvements beyond the medical sector, such as innovation in IT, mobility, material 
sciences, etc. When employing this variable it is therefore important to keep in mind that the 
effect of R&D investments in sciences may be overestimated, as it is not focused exclusively 
on health care R&D expenditure. This variable, however, has been chosen with the purpose to 
include improvements in IT, data analytics, and technological equipment, which also have a 
positive effect on life sciences advancements (The Economist, 2017). Beyond the importance 
of the inclusion of other scientific innovations, the correlation between R&D investments in 
sciences and in health care specifically is 96% in this dataset. Since R&D investments in a 
specific country are highly dependent on external factors, such as socio-political stability, 
cyclical fluctuations, and investor confidence, this study takes decade averages to even out 
exogenous volatility.  
Even though it is clear that technological innovation is not immediately dispersed 
internationally when it is being created, this study examines the international technological 
frontier. This frontier represents the best existing technology in the world and thus is an 
important price-determining factor (in the sense discussed above). As R&D expenditure is a 




fraction of GDP, their changes are expected to be correlated, leading to possible 
multicollinearity problems. By means of summing global investments in R&D in sciences, the 
potential multicollinearity problem between GDP and R&D expenditure is mitigated at a 
country level. This study uses the ten-year averages of international R&D investments on 
sciences as an indicator for technological advances in health care and predicts an effect on 
HCE growth rates. It is important to keep in mind that the effect may be over estimated, by 
means of the variable not being specified on health care, or underestimated as R&D 
investment is only a small component constituting the price of health care services and 
products. 
3. Methodology 
The research methodology applied in this paper starts by testing the validity of the new 
dataset and replicating the main findings of Barros (1998). In a second step, different types of 
R&D investments are added to the model as indicators of technological innovation, to test the 
hypothesis. Based on a decision-tree, different models test variations of R&D expenditure 
proxies, while excluding or including fixed time effects and other non-demographic variables. 
They are compared to one another to address the research question, whether R&D in sciences 
has a positive or negative significant effect on HCE growth. Misspecification and robustness 
tests are run on the final model. 
3.1. General Model 
The General Model is constructed as follows: 
2  𝑑𝑙𝑛𝐻𝐶𝐸!,! = 𝛽! + 𝛽!𝑑𝑙𝑛𝐺𝐷𝑃!,! + 𝛽!𝐒𝐕!,! + 𝛽!𝐅𝐄!,! + 𝛽!𝐷𝑒𝑚𝑜!,! + 𝑒!,! . 
The dependent variable is the first difference of the natural log of HCE (dlnHCE). Here 
dlnHCE is the change in the log of spending by country (i) over time (t) in yearly or decade 
averages of the given data. The explanatory factors are vectors of variables written in bold 
and individual variables are stated in italics. The vector of explanatory system variables 




abbreviated as SV reflects differences in health care funding systems across countries and 
health care access regulations. The vector SV consists of two sets of variables regarding the 
funding type of HCE. The first describes the proportions of HCE of three sources: first, 
coming from government spending or compulsory insurance (compulsory/government), the 
second in form of out-of-pocket (OoP) payments of private funds, and finally payments from 
NGOs and private companies (voluntary). Adding on to this, a dummy for the existence of 
gatekeepers labeled GK is part of the system variables of model. The model also includes a 
variables describing demographic changes (Demo). In this paper, only the share of population 
above the age of 65 is analyzed as a demographic indicator. Beyond that, two types of fixed 
effects (FE) are adopted in this model: First, time fixed effects in the form of dummy 
variables per decade and, second, country fixed effects measured by the starting value of 
HCE. By including the first values of HCE possible relations between growth and levels are 
being taken into account. A detailed description of the variables included in the model is in 
Section 3.3. (Table 1) and a description of all variables in the dataset can be found in 
Appendix B. 
3.2. Model including technological advances  
The General Model includes many relevant factors leading to a better understanding of HCE 
growth. Nevertheless, 40% of HCE growth changes are still not explained by the model 
(Table 2 column 4) and is broadly expected to be attributable to advances in technology 
(Marino et al., 2017). As mentioned in the literature review, this study focuses on the aspect 
of R&D in sciences leading to technological innovation. Beyond influencing the state of 
technology, R&D investments serve as a predictor of HCE growth because it is a component 
of the price for HC. As mentioned in equation (1), the cost of health care comprises R&D 
investments. The next equation summarizes the components of health care costs: 
3  𝑐𝑜𝑠𝑡 𝑜𝑓 𝐻𝐶 = 𝑅&𝐷 +  𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑠𝑡 +⋯+𝑚𝑎𝑟𝑘𝑒𝑡𝑖𝑛𝑔  × 𝑝𝑟𝑜𝑓𝑖𝑡 𝑚𝑎𝑟𝑔𝑖𝑛.  




Other constituents setting the price of health care products are production costs, transportation 
costs, marketing costs, etc. Like other institutions, health care companies are profit-
maximizing entities and thus require profits to justify their existence. This paper assumes that 
the R&D investments explain a large fraction of the development of health care prices and 
thus can explain a fraction of HCE growth.  
The OECD/Eurostat database contains several variables of different R&D expenditure 
classifications. The most general R&D variable contains the entire amount that is being spent 
on R&D, classified as A0 in this study. OECD (2017) describes the variable A0 as total 
expenditure on R&D as a proportion of GDP, in current capital values, by all residents, and 
institutions etc. by country measured as percentage of GDP. The R&D Development Statistics 
Institute breaks the total R&D investments down by different characteristics, such as sector or 
performance, source of funds, type of cost, field of science, and socio-economic objective. 
For this study, the field of science is the most suitable. R&D on sciences (A1) is a fraction of 
A0, and R&D expenditure on natural sciences and engineering (A2) is a subgroup of A1. 
OECD/Eurostat offers data on R&D expenditure on health care (A3) specifically. However, 
with increasing precision of the exact field of investment, the number of data points 
decreases. This information, including the number of observations available according to each 
level of categorization, is depicted in Appendix C. 
The decision of which variable to use for the estimation of technological advances is made as 
follows: A2 and A3 only have 36 and 13 observations respectively. These are too few 
observations for the purpose of this work, so that A2 and A3 are not considered in the further 
analysis. The new model is structured as follows including the R&D investments variable:  
4  𝑑𝑙𝑛𝐻𝐶𝐸!,! = 𝛽! + 𝛽!𝑑𝑙𝑛𝐺𝐷𝑃!,! + 𝛽!𝐒𝐕!,! + 𝛽!𝐅𝐄!,! + 𝛽!𝐷𝑒𝑚𝑜!,! + 𝛽!𝑅&𝐷!,! + 𝑒!,! . 
On a conceptual level, this paper focuses on the inclusion of R&D investments as a predictor 
of global technological advances and as an explanatory variable of HCE growth rates.  




The variable A1, R&D on sciences as the sum of OECD countries without any time lag is 
chosen as most appropriate R&D variable based on the following three steps. In the first step, 
A0 and A1 are compared for suitability as R&D investment variable. The decision is guided 
by two criteria: One is the number of data points, another is the precision of data specific to 
research in the fields associated to health care. The second step is deciding whether to include 
the R&D variable by country or as a sum of all investments in research of the included 
countries. This decision is based on economic reasoning, the avoidance of multicollinearity 
problems, and statistic explanatory power. In the last step, the periods of lags is chosen. This 
decision is grounded in economic reasoning, number of observations, and significance tests as 
well. The decision is explained in more depth in section 4.2 in the above-mentioned structure. 
3.3 Data description 
For the purpose of this study, a new dataset is created based on extractions of the CREDES-
OECD/Eurostat database. The data is publicly available on the website of OECD. The 
variables included are those of 35 OECD countries in an unbalanced data set with data from 
1970 to 2016. Beyond the key explanatory variables analyzed in the context of HCE growth 
studies, additional HCE-related explanatory variables have been included that I plan to use for 
further studies2. Table 1 depicts a list of the variables included in the model and their 
explanations.  
Table 1: List of variables included in the model and their explanations 
Variable name Explanation3  
COUNTRY, 
country 
The 35 OECD countries have been included by three-lettered country abbreviations and 
country codes.  
dlnHCE dlnHCE measures the consumption of health care goods and services (incl. personal health 
care and collective services; excl. spending on investments. It is labeled “Health Spending” 
in the OECD database. Here the first difference of the log is taken in order to be able to 
examine growth effects.  
dlnGDP Gross domestic product (GDP) is the expenditure on final goods and services excl. imports 
measured in million US$ at current prices and PPPs, following System of National Accounts 
(2008 onwards). To match the dependent variable the first difference of the log is taken. 
                                                
2 Appendix B contains a detailed list of variables included in the data set with their 
descriptions. 
3 The variable descriptions are derived from the OECD database and website.  






The vector of system variables (SV) consists of variables describing the country specific 
health care system’s characteristics and its funding sources. The different sources of HCE 
financing, includes government spending, private sources or insurances. Insurance can be 
compulsory and voluntary. If not insured, the patient has to pay out of his/her own pocket. 
This vector of variables consists of the dummy variables: 
- By country specific health care system 
o General Taxation 
o National Insurance  
o System Combination 




- Indicator whether the country has gatekeepers or not 
SysGenTax This dummy variable indicates whether a country has a tax-financed health care system. 
SysNatInsurance It indicates when a country has a statutory social health insurance system.  
SysCombi If a country has a combination of both general tax and national insurance as funding method 
of the health care in the country, then this dummy variable indicates it. 
Gov/compulsory 
 
The amount of the financing arrangements in PPPs which are supported by the government 
or compulsory payments of the citizens, then it will be included in this category.  
Voluntary The amount of the health insurance, which is voluntary and not compulsory, is allotted to 
this classification. They are using PPPs. 
Out-of-pocket The amount of funds that are from a private source e.g. households, NGOs, and private 
companies, measured in PPPs. 
GK Some countries have gatekeepers (GK) to access health care. A gatekeeper is a person who 
coordinates and manages health care plan. He/she approves referrals to specialists, hospitals, 
laboratories, and other medical services (Chandra & Skinner, 2012). 
FE The fixed effects that are being taken into account in this paper are time fixed effects and 




These dummy variables take the time-fixed effects by decade into account. The first decade 
reaches from 1975 to 1984, the second from 1985 to 1994, the third from 1995 to 2004, and 
the fourth from 2005 to 2015. 
startlevel 
startlevel2 
The start levels take the country fixed-effects into account. startlevel takes the level value of 
the specific country in 1975 into account, while startlevel2 is the square-root of the value. 
Demo For simplicity, this study only takes one demographic variable into account. The share of 
elderly population (ElderlyPop) is the variable of interest. It provides information about the 
share of people that are above 65 years of age, measured as a percentage of the population. 
R&D In this context the R&D variable is OECDA1. A1 is the gross domestic expenditure on R&D 
of all sectors of performance and fields of science in million current PPP US$. OECDA1 is 
the sum of all countries’ decade average expenditure on R&D in a year.4 
 
For the empirical tests, average values of 10 years by country are constructed, as in Barros 
(1998). The analysis of decades allows for long-run effects and slow adjustments to be taken 
into account. Furthermore, the problematic characteristic of the dataset of being unbalanced is 
smoothed out by this approach. The explanatory variables reflecting initial conditions, 
controlling for gatekeeping by a dummy variable, and further dummy variables taking 
differing health care systems into account, allow for cross-country comparisons.  
                                                
4 The exact construction of the R&D OECD sum variables is explained in Appendix F. 




4. Results  
4.1. General Model 
The main findings of the General Model using the new dataset are shown in Table 2. It 
reveals that dlnGDP has a positive and significant relation to dlnHCE. When regressing 
dlnHCE on dlnGDP, the result of the adjusted R-squared lies already at 34% (column 5).  
Furthermore, the result of the General Model is that income elasticity of HCE is positive and 
below one (columns 1 to 5), suggesting that HCE is a normal and necessary good, in 
accordance to other results in the literature.  
The system variables, describing the funding sources and local health care system 
characteristics are mostly non-significant. Only out-of-pocket financing (OoP) is significant 
(columns 3 and 4). A 10% increase in OoP suggests a 0,09% increase in HCE growth. It can 
be expected that once patients have to pay out-of-pocket, they will avoid health care spending 
as much as possible. However, the econometric results imply that countries that rely more on 
out-of-pocket expenditure have a higher growth rate in HCE. This can be reasoned by lower 
bargaining power of individuals on health care prices than insurances or governmental agents 
(Ke et al., 2011). The share of the population that is older than 65 in a country (Demo) is not a 
significant indicator of HCE growth (columns 3 and 4). These findings are in line with 
previous research results (Barros, 1998; Okunade & Suraratdecha, 2000; Maisonneuve & 
Martins, 2017).  
Table 2 also shows that the fixed-effects for time and start level of each country (FE) are 
mostly significant (columns 1, 3, and 4). The dummy variables for the decades indicate a 
decrease in growth rate from decade to decade, with a particularly strong negative effect in 
the last decade (4.decade). Also the country-fixed effect, startlevel and startlevel2 yield 
interesting results. When the country’s system variables have been controlled for, the level of 
HCE of the specific country in 1975 does not have a significant effect (comparing columns 1 




and 4). If SV is not controlled for, higher initial levels of HCE are related to slower HCE 
growth rates. This is in line with the expectations of the Solow-Growth and the Convergence 
Theory (Sala-i-Martin & Barro, 2004). 
Table 2: Regression results of the General Model.5 
dlnHCE (1) (2) (3) (4) (5) 
dlnGDP 0.208*** 0.546*** 0.216** 0.216* 0.546*** 
 (0.0735) (0.0783) (0.0891) (0.112) (0.118) 
SysGenTax   0.00881 0.00881  
   (0.00668) (0.00703)  
SysNatInsurance   0.00682 0.00682  
   (0.00612) (0.00681)  
SysCombi   0.0114 0.0114  
   (0.00743) (0.00834)  
Gov/Compulsory   0.00555 0.00555  
   (0.0126) (0.00935)  
Voluntary   0.00526 0.00526  
   (0.0126) (0.00935)  
OoP   0.000982*** 0.000982**  
   (0.000343) (0.000406)  
GK   -0.00113 -0.00113  
   (0.00447) (0.00445)  
2.decade -0.0370***  -0.0328*** -0.0328***  
 (0.00579)  (0.00811) (0.00928)  
3.decade -0.0380***  -0.0290*** -0.0290***  
 (0.00531)  (0.00815) (0.00976)  
4.decade -0.0526***  -0.0414*** -0.0414***  
 (0.00595)  (0.00862) (0.0103)  
Demo   -0.00104 -0.00104  
   (0.000735) (0.000977)  
startlevel -0.000127** -3.10e-06 -1.15e-05 -1.15e-05 -3.10e-06 
 (5.60e-05) (1.45e-05) (6.40e-05) (7.58e-05) (1.71e-05) 
startlevel2 1.45e-07**  2.36e-08 2.36e-08  
 (6.92e-08)0.  (9.07e-08) (1.08e-07)  
Constant 0.113*** 0.0354*** -0.478 -0.478 0.0354*** 
 (0.0132) (0.00821) (1.262) (0.934) (0.00969) 
      
Observations 104 104 83 83 104 
R-squared 0.664 0.348 0.671 0.671 0.348 
Adj. R-squared 0.644 0.336 0.603 0.603 0.336 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
 
When running the General Model with the updated and larger dataset, similar to Barros 
(1998), the R-squared results fit at 65% of the regression (Table 2 column 1). In the next step, 
the inclusion of R&D expenditure is investigated for significance and explanatory power. 
 
                                                
5 Columns 1, 4, and 5 are robust regressions, while columns 2 and 3 are non-robust. 




4.2 Model including technological advances 
This section begins with the three-step approach elaborated in the Methodology section to 
identify the most suitable R&D expenditure variable to test the research question. Thereafter, 
the empirical results of the model are discussed. As a first step, the appropriate R&D variable 
is determined. Despite the fact that R&D on Sciences (A1) has slightly fewer observations 
than the total expenditure on R&D (A0), it makes more sense to choose A1 as an explanatory 
variable rather than A0. Details about the two variables can be found in Appendix D. 
Considering equation 3, the price setting components of health care products and services, it 
is important to focus on R&D in the health care sector as much as possible. Furthermore, 
R&D investments in the fields of sciences do directly and indirectly lead to innovation in the 
health care sector and thus function as good indicator of technological advances. The General 
Model results in positive coefficients for both A0 and A1. However, against the hypothesis at 
test, they are insignificant as can be seen in the regression table Appendix E columns 3 and 4. 
The second step involves the measurement of A1 in the model. The R&D investment by 
country is denoted by the variable name A1, while the decade average of the sum of all OECD 
countries is denoted as OECDA16. The development of the technological innovation frontier 
occurs at a global level. For this reason, it makes sense to aggregate the R&D investments of 
the analyzed countries to proxy for international innovation development. Furthermore, when 
regressing the R&D expenditure of sciences by country on the variables of the General Model 
to explain the movement of HCE growth, it is crucial to check for multicollinearity issues 
between explanatory variables. In economic upswings, the ability and willingness to invest in 
R&D is higher, while recessions are usually accompanied by lower amounts of investments. 
This co-movement of R&D investments and GDP development by country is another reason 
to analyze the aggregate value of the R&D investments. In Table 3 columns 2, 4, and 5 the 
                                                
6 The exact computation of this variable is described in Appendix F. And a graph of A1 and 
OECDA1 over time is depicted in Appendix F as well. 




coefficient has a negative sign, suggesting that more R&D investments in OECD countries is 
related to lower HCE growth.  
Table 3: Regression Results of Model including A1 and OECDA1 
dlnHCE (1) (2) (3) (4) (5) 
dlnGDP 0.487*** 0.312*** 0.235** 0.216* 0.320*** 
 (0.0893) (0.100) (0.101) (0.112) (0.112) 
A1 1.59e-08  1.14e-07   
 (3.76e-08)  (7.23e-08)   
OECDA1  -9.07e-08***  -1.13e-07*** -4.62e-08** 
  (1.47e-08)  (2.81e-08) (2.20e-08) 
SysGenTax   0.0131** 0.00881 0.0103 
   (0.00538) (0.00703) (0.00732) 
SysNatInsurance   0.00489 0.00682 0.00961 
   (0.00622) (0.00681) (0.00799) 
SysCombi   0.0129* 0.0114 0.0105 
   (0.00659) (0.00834) (0.00839) 
Gov/Compulsory   -0.00377 0.00555 0.0103 
   (0.00829) (0.00935) (0.00980) 
Voluntary   -0.00444 0.00526 0.0101 
   (0.00827) (0.00935) (0.00985) 
OoP   0.000851** 0.000982** 0.000947** 
   (0.000383) (0.000406) (0.000434) 
GK   0.00150 -0.00113 -0.00121 
   (0.00470) (0.00445) (0.00468) 
2.decade   -0.0217*** -0.0145**  
   (0.00777) (0.00613)  
3.decade   -0.0190** 0.0164***  
   (0.00855) (0.00462)  
4.decade   -0.0301***   
   (0.00927)    
Demo   -0.00130 -0.00104 -0.00143 
   (0.000943) (0.000977) (0.000947) 
startlevel 2.37e-06 -1.99e-05 -7.71e-05 -1.15e-05 4.97e-05 
 (1.49e-05) (1.42e-05) (7.11e-05) (7.58e-05) (8.77e-05) 
startlevel2   1.22e-07 2.36e-08 -5.18e-08 
   (9.66e-08) (1.08e-07) (1.26e-07) 
Constant 0.0366*** 0.0951*** 0.462 -0.459 -0.979 
 (0.00972) (0.0124) (0.825) (0.935) (0.983) 
      
Observations 100 104 79 83 83 
R-squared 0.321 0.540 0.585 0.671 0.581 
Adj. R-squared 0.300 0.526 0.487 0.603 0.509 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
Comparing columns 4 and 5 in Table 3, it can be seen that when omitting the decade 
dummies, the explanatory power of the model decreases by about 10%. When including 
OECDA1 the dummy variable 4.decade, which is significant in the General Model, is 
automatically removed due to multicollinearity. This makes economic sense, because the 
inclusion of OECDA1 is to approximate the changes of technological advances over time. 




Including OECDA1 imposes a systemic change over time that captures part of the fixed-
effects. To make sure that the model is not misspecified some tests will be run in section 5. 
Furthermore, when comparing Columns 1 and 2 of Table 3, the adjusted R-squared suggests 
that the inclusion of the variable OECDA1 yields a higher explanatory power of the entire 
model than A1. The regression output shows that 30% of the HCE growth changes are 
explained when including A1, versus 52% explanatory power when including OECDA1.  
In a third and last step of this variable identification process, the number of lags to be 
included in the model is determined. Technological innovation is a lengthy process of 
continued R&D investments. Pharmaceutical drug developments are especially volatile and 
outcomes are unpredictable, as it takes decades for them to finally enter the market. Although 
it makes economic sense to include lags, Table 4 shows that the empirical results are not 
significant. Furthermore the inclusion of lagged variables of OECDA1 in columns 3 to 5 does 
not increase the explanatory power of the model. This can be seen by the lower R-squared 
values, which may be due to fewer observations available with each additional lag. To control 
for this, the adjusted R-squared is applied yielding similar results. The only R&D variable 
that is significant in the model is the non-lagged variable of R&D expenditure in sciences. 
This could be because the lagged values of OECDA1 averages over ten years are not 
sufficiently sensitive to yearly-changes and variation over time is lost. Adding this variable to 
the existing model increases the explanatory power of the model from 47.8% to 50.9%, as can 
be seen in the Table 4, columns 1 and 2 by the adjusted R-squared values.  
The economic interpretation of OECDA1 on dlnHCE is as follows: A 10% increase in R&D 
investments in sciences in OECD countries leads to a decrease of 0.25% in HCE a year on 
average. There are at least two ways to explain the negative relation. The first is that the 
aggregate OECDA1 variable captures effects beyond those previously incorporated in the 
HCE growth determinant analysis. The second reason is that there may be differences on how 




R&D affects HCE growth depending on the growth of R&D itself. This reasoning however 
has not been thoroughly investigated yet.  
Table 4: Regression Results of Model including OECDA1 and lags 
dlnHCE (1) (2) (3) (4) (5) 
dlnGDP 0.416*** 0.320*** 0.411*** 0.440*** 0.413*** 
 (0.110) (0.112) (0.116) (0.123) (0.118) 
OECDA1  -4.62e-08**    
  (2.20e-08)    
lag1OECDA1   -3.15e-09   
   (1.46e-08)   
lag2OECDA1    -1.54e-08  
    (1.25e-08)  
lag3OECDA1     -5.41e-10 
     (1.54e-08) 
SysGenTax 0.0114 0.0103 0.0113 0.0122 0.0117 
 (0.00803) (0.00732) (0.00808) (0.00818) (0.00811) 
SysNatInsurance 0.0114 0.00961 0.0112 0.0119 0.0114 
 (0.00825) (0.00799) (0.00840) (0.00845) (0.00865) 
SysCombi 0.00805 0.0105 0.00838 0.00844 0.00801 
 (0.00852) (0.00839) (0.00866) (0.00864) (0.00861) 
Gov/Compulsory 0.0103 0.0103 0.00999 0.00927 0.0105 
 (0.0101) (0.00980) (0.0111) (0.00998) (0.00987) 
Voluntary 0.00998 0.0101 0.00966 0.00888 0.0102 
 (0.0102) (0.00985) (0.0112) (0.0101) (0.00994) 
OoP 0.00100** 0.000947** 0.00103** 0.00110** 0.000995** 
 (0.000450) (0.000434) (0.000461) (0.000449) (0.000465) 
GK -0.000558 -0.00121 -0.000743 -0.000678 -0.000458 
 (0.00468) (0.00468) (0.00471) (0.00474) (0.00480) 
Demo -0.00191** -0.00143 -0.00185* -0.00193** -0.00195** 
 (0.000905) (0.000947) (0.000971) (0.000903) (0.000955) 
startlevel 8.81e-05 4.97e-05 8.32e-05 8.82e-05 8.98e-05 
 (9.28e-05) (8.77e-05) (9.90e-05) (9.41e-05) (9.64e-05) 
startlevel2 -9.60e-08 -5.18e-08 -8.94e-08 -9.17e-08 -9.81e-08 
 (1.33e-07) (1.26e-07) (1.41e-07) (1.35e-07) (1.37e-07) 
Constant -1.002 -0.979 -0.970 -0.896 -1.024 
 (1.015) (0.983) (1.117) (1.001) (0.987) 
      
Observations 83 83 82 81 80 
R-squared 0.548 0.581 0.541 0.550 0.543 
Adj. R-squared 0.478 0.509 0.461 0.471 0.461 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
5. Tests 
This section tests the model for specification strength and robustness. To test the model 
specification, the Ramsey RESET test is run. This test examines the null hypothesis that there 
are no omitted variables in the model. When running this test on the General Model, the null 
hypothesis is rejected; suggesting that there are omitted variables in the model. When testing 
the model including the R&D expenditure variable it yields significant results suggesting that 




the null hypothesis cannot be rejected and implying that there are no omitted variables in this 
model. The test results are to be found in Appendix G. 
When working with OLS it is important to understand the characteristics of the variance of 
the error terms. If they are homoscedastic, the OLS model can be applied. Otherwise, 
whenever the error terms variance is heteroscedastic, the OLS results are biased and t- and F- 
statistics inappropriate. This bias has been taken into account when running the regressions on 
the final model. The results between non-robust and robust regressions are similar, so there is 
no reason to expect heteroscedasticity in the error terms. 
6. Final Remarks  
In this study the following research question is being studied: How does R&D expenditure in 
sciences affect HCE growth? The economic reasoning behind this is that R&D investments 
are used as a proxy for technological improvements that should help explain the development 
of HCE growth. Previous studies agree that technological improvements should affect HCE 
growth through different channels. However, whether the effect has a positive or negative 
coefficient is heavily debated. It is even possible that the effects in opposing directions may 
offset each other.  
The sum of 10-year averages of international R&D investments is the most suitable variable 
for these studies. It focuses on the global technological frontier development. It was chosen 
based on the following criteria: solid economic reasoning, maintaining sufficiently many 
observations, and based on econometric findings. A shortcoming of this model is the limited 
availability R&D expenditure data on specific industries. Despite the Ramsey RESET test 
suggesting that there are no omitted variables, it can still be the case that there are better 
explanatory variables than the ones chosen in this model. Other studies have included 
behavioral and environmental cues such as amount of alcohol consumed per inhabitant 




(Kringos et al., 2015), number of frequent smokers (Clements et al., 2012), and environmental 
pollution (Narayan & Narayan, 2007) to study their effects on HCE. These aspects can also be 
included in HCE growth studies. 
Including this variable in the General Model creates the new model, as indicated in equation 
4, with the regression output of Table 4 column 2. The addition of R&D expenditure for 
sciences, as a sum of 10-year averages of all OECD country investments has a significant but 
negative effect on HCE growth. Despite R&D investments in sciences generating new 
technologies, which are enabling people with previously fatal diseases to live longer and 
consume a possibly higher quantity of medications over a longer period of time, technological 
innovation is not leading to higher HCE growth as previous literature supposes. Amongst 
others, the effect of cheaper and faster medical procedures, and better preventive measures 
due to technological improvements in the health care sector and other sciences are slowing 
down HCE growth. Given more specific data points in future, it may be possible to 
disaggregate the effects of patient care and services, pharmaceuticals and biochemistry, 
machinery, and data collection and analytics R&D investments for example, to better 
understand their individual roles on innovation and HCE growth. It is possible that different 
R&D fields yield effects in opposing directions. More detailed data may allow for a better 
identification of growth accelerators and hampering factors as well as identifying changes in 
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7. Appendix 
Appendix A: Literature review summary table  
 
Driver of HCE growth Main variables controlled for Following authors have 
studied this topic (amongst 
others) 
Demographic factors Share of elderly population (65+), 
Share of young (15-) 
Hitris (1992) 
Death-related costs Aprile & Palombi (2006) 
Non-demographic 
factors  
GDP growth, Income per capita Newhouse (1992) 
Time and country fixed effects Freeman (2003) 
Baumol effect: Wage exceeding 
general productivity in a sector  
Hartwig (2008) 
Baumol & Malach (2009) 
Health system Systems access  Chandra & Skinner (2012) 
Gatekeepers Joumard et al., (2010) 
Technological 
Innovation  
Infant mortality, life expectancy Marino et al. (2017) 
Share of patents & R&D statistics  Maisonneuve & Oliveira 
Martins (2017) 
Others Pollution Narayan & Narayan (2007) 
Smoking Lightwood & Glantz (2016) 










Appendix B: List of relevant variables and vectors of variables included in dataset 
Variable name Explanation7  
COUNTRY, country The 35 OECD countries have been included by three-lettered country 
abbreviation and country code: 
Australia (AUS), Austria (AUT), Belgium (BEL), Canada (CAN), 
Switzerland (CHE), Chile (CHL), Czech Republic (CZE), Germany 
(DEU), Denmark (DNK), Spain (ESP), Estonia (EST), Finland 
(FIN), France (FRA), Great Britain (GBR), Greece (GRC), Hungary 
(HUN), Ireland (IRL), Iceland (ISL), Israel (ISR), Italy (ITA), Japan 
(JPN), Korea (KOR), Luxembourg (LUX), Latvia (LVA), Mexico 
(MEX), Netherlands (NLD), Norway (NOR), New Zealand (NZL), 
Poland (POL), Portugal (PRT), Slovakia (SVK),  Slovenia (SVN), 
Sweden (SWE), Turkey (TUR), and United States of America 
(USA). 
HCE HCE measures the consumption of health care goods and services 
(incl. personal health care and collective services; excl. spending on 
investments. It is labeled “Health Spending” in the OECD database. 
HCE is financed through different combinations of sources, incl. 
government spending, private sources or insurances. Insurance can 
be compulsory and voluntary. If not insured, the patient has to pay 
out of his/her own pocket.  
dlnHCE Here the first difference of the log is taken in order to be able to 
examine growth effects. 
GDP Gross domestic product is the expenditure on final goods and 
services excl. imports measured in million US$ at current prices and 
PPPs, following System of National Accounts (2008 onwards). 
“Gross”: There have been no deductions made to take depreciation of 
capital into account.  
“Domestic”: Local institutional units of country’s production. 
“Product”: Final consumption goods and services. 




The vector of system variables (SV) consists of variables describing 
the country specific health care system’s characteristics and its 
funding sources. The different sources of HCE financing, includes 
government spending, private sources or insurances. Insurance can 
be compulsory and voluntary. If not insured, the patient has to pay 
out of his/her own pocket. This vector of variables consists of the 
dummy variables: 
- By country specific health care system 
o General Taxation 
o National Insurance  
o System Combination 
 
                                                
7 All variable descriptions are derived from the OECD database and website.  








- Indicator whether the country has gatekeepers or not 
SysGenTax This dummy variable indicates whether a country has a tax-financed 
health care system. 
SysNatInsurance This dummy variable indicates when a country has a statutory social 
health insurance system. 
SysCombi If a country has a combination of both general tax and national 
insurance as funding method of the health care in the country, then 
this dummy variable indicates it. 
Gov/compulsory 
 
The amount of the financing arrangements in PPPs which are 
supported by the government or compulsory payments of the 
citizens, then it will be included in this category. 
Voluntary The amount of the health insurance, which is voluntary and not 
compulsory, is allotted to this classification. They are using PPPs. 
Out-of-pocket The amount of funds that are from a private source e.g. households, 
NGOs, and private companies, measured in PPPs. 
GK Some countries have gatekeepers (GK) to access health care. A 
gatekeeper is a person who coordinates and manages health care 
plan. He/she approves referrals to specialists, hospitals, laboratories, 
and other medical services (Chandra & Skinner, 2012). 
FE The fixed effects that are being taken into account in this paper are 
time fixed effects and country specific fixed effects, categorized by 




These dummy variables take the time-fixed effects by decade into 
account. The first decade reaches from 1975 to 1984, the second 
from 1985 to 1994, the third from 1995 to 2004, and the fourth from 
2005 to 2015. 
startlevel 
startlevel2 
The start levels take the country fixed-effects into account. startlevel 
takes the level value of the specific country in 1975 into account, 
while startlevel2 is the square-root of the value in 1975. 
Demo For simplicity, this study only takes one demographic variable into 
account. The share of elderly population (ElderlyPop) is the variable 
of interest. It provides information about the share of population that 
is of 65+ years of age, measured as percentage of total population. 
R&D In this context the R&D variable is OECDA1. A1 is the gross 
domestic expenditure on R&D of all sectors of performance and 
fields of science in million current PPP US$. OECDA1 is the sum of 
all countries’ decade average expenditure on R&D in a year. 
LOH Length of stay in hospitals: Average number of days spent in 
hospitals by patients. It is calculated by dividing the total number of 
days by all inpatients in a year by number of admissions/discharges. 
Life expectancy at 65 Life expectancy at the age of 65 is the average number of years a 
person is expected to live, given that age-specific mortality levels are 
constant. It is measured in years. The calculation methodology of life 
expectancy can differ slightly between countries.  





spending as % of 
GDP 
Expenditure on prescription medication and over-the-counter 
medication, excl. pharmaceuticals consume in hospitals. Retail, 
wholesale margins, and VAT are included. It is measured as share of 
GDP. Variation across countries, are due to the inclusion of other 
medical non-durable goods in some countries. 
Infant mortality Number of deaths of children below 1 year of age, measured per 
1.000 live births. Variations in reporting between countries are due to 
differing registering practices. 
Potential of years of 
life lost 
Potential of years of life (PYLL) lost indicates the measure of 
premature/preventable deaths, measured in years per 100.000 
inhabitants, aged 0-69. It is calculated by summing up deaths 
occurring at every age, then multiplying it with the residual years to 
live up to 70. To take country differences into account they are 
standardized by country each year. 
Public spending on 
incapacity total % of 
GDP 
Expenditure incurred due to sickness, occupational injury, and 
sickness, excl. cases of family cash benefits; incl. social expenditure 
on services and other benefits. This indicator is measured as 
percentage of GDP. 
Unemployment rate Unemployment rate encompasses the number of people who are 
unemployed ad a percentage of labour force. The labour force is 
defined as consisting of unemployed and employed, be it paid or 
self-employed. To be considered unemployed, the person has to 
report that he/she is without work, but available to do so and is 
taking active steps to find work in the last four weeks.  
Wage levels Split into low and high pay, wage levels refer to full-time employees, 
measured in percentage. Low pay refers to the share of workers 
earning less than 2/3 of median earnings, while high pay refers to 
those earning more than 1,5 of median earnings. 
Alcohol consumption This indicator is defined as annual sales of pure alcohol in liters per 
person above 15 years of age.  
Daily Smokers This measure shows the percentage of population that is an every day 
smoker above the age of 15. 
Life expectancy at 
birth 
This measure states how long, on average, a newborn is expected to 
live, given that current death rates remain constant. This indicator is 
measured in number of years of expected life. 
Elderly Population Share of population 65 years of age and older measured as a 
percentage of total population. 
Young Population Share of population that is younger than 15 years of age, measured as 
a percentage of total population. 
Working age 
population 
Share of population between 15-64 years of age measured as 
percentage of total population. 
Social Security 
Contributions 
Compulsory payments to government for future social benefits 
measured in percentage of GDP. 




A0 - Gross domestic 
spending on R&D 
Total expenditure on R&D, current and capital, by all residents, 
institutes, and governmental institutions etc. by country, incl. funding 
from abroad, measured as percentage of GDP. 
A1 – All fields of 
science 
Gross domestic expenditure on R&D of all sectors of performance 
and fields of science in million current PPP US$. 
Note that sector totals and subcategories do not necessarily add up, 
as some small percentages of R&D expenditure are not allocated to 
any of the given sectors. 
A2 – Natural sciences 
and engineering 
R&D on natural sciences & engineering measured in million current 
PPP US$. 
A3 – Medical and 
Health Sciences 
R&D on medical & health sciences engineering measured in million 
current PPP US$.  
A5 – All Socio-
Economic objectives  
R&D with socioeconomic objective based on NABS 2007 
classification engineering measured in million current PPP US$. 
A4 – Health  R&D with socioeconomic objective focusing on health engineering 
measured in million current PPP US$. 
 
  



























Appendix D: Descriptive information about A0 and A1 
  Variable Obs    Mean Std. Dev. Min Max 
A0 107 24238.39 58298.24 39.57431 409126.5 
A1 104 15718.99 34368.69 23.98367 243394.9 
 
There exists a pairwise correlation between A0 and A1 of 97%.  




Appendix E: Regression output of General Model including A0 and A1 
dlnHCE (1) (2) (3) (4) 
     
dlnGDP 0.208*** 0.216* 0.189* 0.235** 
 (0.0735) (0.112) (0.105) (0.101) 
A0   4.18e-08  
   (4.41e-08)  
A1    1.14e-07 
    (7.23e-08) 
SysGenTax  0.00881 0.00955 0.0131** 
  (0.00703) (0.00597) (0.00538) 
SysNatInsurance  0.00682 0.00478 0.00489 
  (0.00681) (0.00631) (0.00622) 
SysCombi  0.0114 0.0102 0.0129* 
  (0.00834) (0.00743) (0.00659) 
Gov/Compulsory  0.00555 0.000739 -0.00377 
  (0.00935) (0.00811) (0.00829) 
Voluntary  0.00526 0.000118 -0.00444 
  (0.00935) (0.00809) (0.00827) 
OoP  0.000982** 0.000778** 0.000851** 
  (0.000406) (0.000375) (0.000383) 
GK  -0.00113 0.00166 0.00150 
  (0.00445) (0.00470) (0.00470) 
2.decade -0.0370*** -0.0328*** -0.0230*** -0.0217*** 
 (0.00579) (0.00928) (0.00776) (0.00777) 
3.decade -0.0380*** -0.0290*** -0.0198** -0.0190** 
 (0.00531) (0.00976) (0.00865) (0.00855) 
4.decade -0.0526*** -0.0414*** -0.0319*** -0.0301*** 
 (0.00595) (0.0103) (0.00934) (0.00927) 
Demo  -0.00104 -0.00131 -0.00130 
  (0.000977) (0.000877) (0.000943) 
startlevel -0.000127** -1.15e-05 -5.57e-05 -7.71e-05 
 (5.60e-05) (7.58e-05) (6.95e-05) (7.11e-05) 
startlevel2 1.45e-07** 2.36e-08 8.67e-08 1.22e-07 
 (6.92e-08) (1.08e-07) (9.55e-08) (9.66e-08) 
Constant 0.113*** -0.478 0.0161 0.462 
 (0.0132) (0.934) (0.808) (0.825) 
     
Observations 104 83 82 79 
R-squared 0.664 0.671 0.566 0.585 
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
 
  




Appendix F: Construction of OCEDA1 
The R&D investments in sciences (A1) value is retrieved from the OECD website by year and 
by country. As a first step, the ten-year average by country is computed. The second step 
sums the results of each decade of all OECD country R&D investments up.  
 
(The Stata commands: 
1. A1GDEonRDScience10yrmean = mean(A1GDEonRDScience) by decade by country  
2. OEVDA1V2=sum(A1GDEonRDScience10yrmean)) 
 












Appendix G: Test results as Stata-Output 
Ramsey RESET test results: 
General Model results of Ramsey RESET test using powers of the independent variables. 
Ho:  model has no omitted variables 
                  F(23, 50) =      2.81 
                  Prob > F =      0.0011 
 
New model results of Ramsey RESET test. 
Ho:  model has no omitted variables  
   F(23, 42) =      1.19;    
Prob > F =      0.3065 
 
Heteroscedasticty of errors test results: 
In this study the “hettest” is applied to detect linear forms of heteroscedasticty. It is also 
known as the Breusch-Pagan test. This test shows the following results given the new model 
with the R&D investments variable incldued: 
Source 
Chi2 df p 
Heteroscedasticity 81.01 75 0.2973 
Skewness 27.69 12 0.0061 
Kurtosis 1.67 1 0.1958 
Total 110.37 88 0.0536 
Breusch-Pagan / Cook-Weisberg test for heteroskedasticity  
         Ho: Constant variance 
         Variables: fitted values of dlnHCE10yrmean 
           chi2(1)      =    19.70 
           Prob > chi2  =   0.0000 
 
 
 
 
 
 
